Skip to content
Biodatica
Start free

Novo Nordisk A/S

Barcelona, California

Phase IIIListed · NVO

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Sign in to watch

What changed

Phase II trial registered: A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes

1w agoTrial registeredJul 9, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Aug 27, 2026

    Diabetes Mellitus, Type 2 · WITHDRAWN · sponsor: Novo Nordisk A/S · A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes

    ClinicalTrials.gov · NCT07357740 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    May 21, 2026

    Obesity, Type 2 Diabetes · RECRUITING · sponsor: Novo Nordisk A/S · A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

    ClinicalTrials.gov · NCT07564414 (opens the source filing in a new tab)

  3. Trial

    Study registered

    Nov 10, 2025

    Obesity · ENROLLING_BY_INVITATION · sponsor: Novo Nordisk A/S · WEgovy Real World Assessment of Weight Loss in Korea

    ClinicalTrials.gov · NCT07280221 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Dec 2, 2024

    Obesity · COMPLETED · sponsor: Novo Nordisk A/S · A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity

    ClinicalTrials.gov · NCT06716307 (opens the source filing in a new tab)

  5. Trial

    PHASE3 registered

    Mar 26, 2024

    Type 2 Diabetes · COMPLETED · sponsor: Novo Nordisk A/S · A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin

    ClinicalTrials.gov · NCT06323161 (opens the source filing in a new tab)

  6. Trial

    PHASE3 registered

    Mar 19, 2024

    Type 2 Diabetes · COMPLETED · sponsor: Novo Nordisk A/S · A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

    ClinicalTrials.gov · NCT06323174 (opens the source filing in a new tab)

  7. Trial

    PHASE3 registered

    Jan 16, 2024

    Type 2 Diabetes · COMPLETED · sponsor: Novo Nordisk A/S · A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

    ClinicalTrials.gov · NCT06221969 (opens the source filing in a new tab)

  8. Trial

    Study registered

    Jul 28, 2022

    Diabetes Mellitus, Type 2 · COMPLETED · sponsor: Novo Nordisk A/S · A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice

    ClinicalTrials.gov · NCT05443334 (opens the source filing in a new tab)

  9. Trial

    PHASE3 registered

    Nov 30, 2021

    Diabetes Mellitus, Type 2 · COMPLETED · sponsor: Novo Nordisk A/S · A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

    ClinicalTrials.gov · NCT05013229 (opens the source filing in a new tab)

  10. Trial

    PHASE3 registered

    Jun 15, 2021

    Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2 · COMPLETED · sponsor: Novo Nordisk A/S · Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes

    ClinicalTrials.gov · NCT04916470 (opens the source filing in a new tab)

  11. Trial

    PHASE3 registered

    Apr 28, 2021

    Diabetes Mellitus, Type 2, Chronic Kidney Disease · COMPLETED · sponsor: Novo Nordisk A/S · A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

    ClinicalTrials.gov · NCT04865770 (opens the source filing in a new tab)

  12. Trial

    PHASE3 registered

    Mar 5, 2021

    Diabetes Mellitus, Type 2 · COMPLETED · sponsor: Novo Nordisk A/S · A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin

    ClinicalTrials.gov · NCT04770532 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources